Xintela AB (ST:XINT) — Market Cap & Net Worth
Market Cap & Net Worth: Xintela AB (XINT)
Xintela AB (ST:XINT) has a market capitalization of $13.70 Million (Skr127.31 Million) as of August 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #26213 globally and #552 in its home market, demonstrating a -4.74% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xintela AB's stock price Skr0.18 by its total outstanding shares 703356359 (703.36 Million). See Xintela AB capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
Xintela AB Market Cap History: 2016 to 2026
Xintela AB's market capitalization history from 2016 to 2026. Data shows change from $295.20 Million to $13.70 Million (-26.10% CAGR).
Index Memberships
Xintela AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.92 Billion | 0.09% | #139 of 281 |
Weight: Xintela AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Xintela AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xintela AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.93x
Xintela AB's market cap is 5.93 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $295.20 Million | $3.00K | -$18.06 Million | 98400.09x | N/A |
| 2017 | $240.70 Million | $2.00K | -$21.95 Million | 120350.88x | N/A |
| 2018 | $452.64 Million | $1.63 Million | -$26.27 Million | 278.03x | N/A |
| 2019 | $314.88 Million | $38.00K | -$43.55 Million | 8286.32x | N/A |
| 2023 | $20.51 Million | $78.00K | -$54.08 Million | 262.98x | N/A |
| 2024 | $24.98 Million | $4.21 Million | -$39.19 Million | 5.93x | N/A |
Competitor Companies of XINT by Market Capitalization
Companies near Xintela AB in the global market cap rankings as of August 4, 2026.
Key companies related to Xintela AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Xintela AB Historical Marketcap From 2016 to 2026
Between 2016 and today, Xintela AB's market cap moved from $295.20 Million to $ 13.70 Million, with a yearly change of -26.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr13.70 Million | -36.27% |
| 2025 | Skr21.50 Million | -13.94% |
| 2024 | Skr24.98 Million | +21.77% |
| 2023 | Skr20.51 Million | -44.64% |
| 2022 | Skr37.05 Million | -78.62% |
| 2021 | Skr173.34 Million | -34.01% |
| 2020 | Skr262.65 Million | -16.59% |
| 2019 | Skr314.88 Million | -30.43% |
| 2018 | Skr452.64 Million | +88.05% |
| 2017 | Skr240.70 Million | -18.46% |
| 2016 | Skr295.20 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Xintela AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.70 Million USD |
| MoneyControl | $13.70 Million USD |
| MarketWatch | $13.70 Million USD |
| marketcap.company | $13.70 Million USD |
| Reuters | $13.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xintela AB
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indicati… Read more